White Rock Capital

What White Rock Capital does

White Rock Capital (WRC) is a private investment management firm founded in 1993 and headquartered in Dallas, Texas. The firm operates three investment strategies under a unified dual mandate of generating absolute positive returns and delivering measurable human impact: a long equity strategy with concentrated positions, a short-selling strategy, and a venture capital strategy that originates private company investments at favorable entry valuations. Deal flow is sourced through proprietary industry relationships rather than traditional Wall Street channels, and the portfolio is characterized by concentrated, high-conviction positions focused on special situations and evolving major themes.

WRC's investment products are not technology platforms but rather discretionary investment mandates, with realized value flowing through portfolio company exits, IPOs, and acquisitions rather than recurring fees disclosed publicly. The firm's current private investments are concentrated in clinical-stage biotechnology: Renovion (respiratory therapies including ARINA-1), Myrtelle (gene therapy for neurological white matter diseases), and Biotheryx (first-in-class protein degraders for cancer and inflammatory disease). The firm is founder-controlled by General Partners Tom Barton and Joe Barton, each with over 35 years of investing experience, including management of the largest U.S. short-selling fund during the 1980s, General Partnership of long/short hedge funds and managed accounts, and venture capital activity.

The business model relies on capital appreciation from concentrated private and public positions, with notable prior realizations including the Novartis acquisition of Avexis for $8.7 billion in May 2018, the PTC Therapeutics acquisition of Agilis Biotherapeutics for up to $1.053 billion in July 2018, and the Microtune IPO at approximately $3 billion valuation in August 2000. WRC was a co-founder of Avexis (then Biolife) in 2011 and the first investor in Agilis in 2013. The firm's co-investor base has historically included Soros Fund Management in deals such as Microtune and Hain Celestial. Pricing, AUM, and management fee structures are not publicly disclosed.

Name

White Rock Capital

Legal name

White Rock Capital

Website

https://wrctx.com

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Investment Management

NAICS

Other Financial Investment Activities (5239), All Other Financial Investment Activities (52399)

akta.pro primary industry

Strategic / Balance-Sheet CVC (On-balance-sheet investing) (FSANAHAA)

Keywords

• Investment management
• Venture capital
• Long short equity
• Private investments
• Hedge fund strategies

Headquarters

HQ city

Dallas

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations

Revenue model

1. Investment Returns from Portfolio Companies: WRC generates returns through equity investments in private and public companies across long, short, and venture capital strategies. Revenue is realized through portfolio company exits, acquisitions, and IPOs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

White Rock Capital (WRC) is a private investment management firm founded in 1993 that pursues absolute positive returns across long, short, and venture capital strategies. The firm sources ideas from industry sources rather than traditional Wall Street channels, maintains concentrated portfolio positions, and originates private company investments with favorable entry valuations, applying a dual mandate to generate superior investment returns and deliver measurable human impact.

Product overview

White Rock Capital is an investment management firm offering a unified suite of investment services across three strategies: Long, Short, and Venture Capital. The firm leverages a dual mandate to generate superior investment returns and deliver measurable human impact. Their investment approach focuses on special situations and evolving major themes, with portfolio composition characterized by concentrated positions. Ideas are sourced from industry sources rather than traditional Wall Street, and they originate private company investments with favorable entry valuations. The firm was founded in 1993 and currently holds private investments in clinical-stage biotech companies including Renovion (lung health therapies), Myrtelle (gene therapy for neurological diseases), and Biotheryx (protein degraders for cancer and inflammatory disease).

Differentiator

Problem solved

Functional benefit

Products and services

• Long Strategy Long equity investment strategy seeking absolute positive returns by maintaining concentrated positions in selected securities.
• Short Strategy Short-selling investment strategy designed to generate returns from declining security prices.
• Venture Capital Strategy Venture capital strategy focused on originating private company investments with excellent entry valuations, particularly in emerging opportunities across various industries.

Quantifiable outcome

• Multiple successful exits including Avexis ($8.7B acquisition by Novartis), Agilis ($1.053B by PTC Therapeutics), and Microtune ($3B valuation at IPO)

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered minor.

• National Taiwan University (NTU) HospitalminorStrategic or Co-development PartnerInternational collaboration led by Agilis with NTU Hospital and the TRND program of NCATS at NIH for gene therapy clinical trials for AADC deficiency.
• National Institutes of Health (NIH) / NCATS / TRNDminorStrategic or Co-development PartnerAgilis collaborated with the Therapeutics for Rare and Neglected Diseases (TRND) program of the National Center for Advancing Translational Sciences at NIH for AADC gene therapy development.

Scale indicators5 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• RA Capital Management: Healthcare-focused crossover fund with both public equity and private investment strategies. Comparable to WRC in running concentrated biotech positions and backing late-stage private companies.
• venBio Partners: Biotech-focused venture firm investing in therapeutic companies. Comparable to WRC's venture capital strategy in clinical-stage biotech.
• EcoR1 Capital: Biotech-focused investment firm with both public and private equity strategies. Comparable multi-strategy approach to WRC's biotech-heavy investment portfolio.
• OrbiMed Advisors: Healthcare-dedicated investment firm with private equity, venture, and public equity strategies across biotech, medical devices, and diagnostics. Comparable multi-strategy healthcare investing model to WRC.
• ARCH Venture Partners: Early-stage deep tech and biotech venture firm. Comparable to WRC's venture capital strategy in incubating breakthrough science companies.
• Deerfield Management: Healthcare investment firm with private equity, venture, and public equity strategies. Comparable full-stack healthcare investment model to WRC's multi-strategy approach.
• Perceptive Advisors: Healthcare and biotech-focused investment firm with venture, credit, and public equity strategies. Comparable to WRC's diversified healthcare investment mandate.
• Baker Brothers Life Sciences: Healthcare and biotech-focused long/short and crossover fund. Compares directly to WRC's biotech-heavy investment approach and similar positioning at the intersection of public/private healthcare investing.

Others

• BridgeBio Pharma: Biotech company developing therapies for genetic diseases with model of creating and incubating portfolio companies. Comparable to WRC's portfolio company approach in rare disease biotech.

Regional players

• Maverick Capital: Dallas-based long/short equity fund. Comparable to WRC as a Dallas-based multi-strategy investment firm, though Maverick focuses more broadly on public equities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/white-rock-capital-tx

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about White Rock Capital